Avacta Group Regulatory News (AVCT)

Avacta Group plc

("Avacta" or "the Group")

Notice of Interim Results

Avacta Group plc (AIM:AVCT), a global provider of innovative diagnostic tools, consumables and reagents aimed at reducing the cost of human and animal healthcare, will be announcing its Interim Results, for the six month period ended 31 January 2013, on Tuesday, 30 April 2013.

An analyst briefing given by Alastair Smith, Chief Executive Officer, and Tim Sykes, Chief Financial Officer, will be held at 09:30 hrs on Tuesday, 30 April 2013 at Abchurch Communications, 125 Old Broad Street, London EC2N 1AR.

-Ends-

For further information please contact:

Notes to Editors:

Avacta Group plc is a global provider of innovative technologies, consumables and reagents for the life science markets, from drug discovery to diagnostics.

Avacta's products address one of the most significant global challenges facing mankind today - the rapidly rising cost of healthcare for a growing and ageing population.

The cost of healthcare is driven by many factors. New drugs are expensive to develop, most don't reach the patient and those that do are often very costly to prescribe. Inadequate, incorrect or slow diagnosis causes delays that lead to longer or less effective courses of treatment resulting in lengthy or repeated hospitalisation.

Avacta is dedicated to developing and providing innovative and practical tools to help drug developers get their products to market quicker and more reliably, and to providing clinicians with rapid and powerful diagnostics to improve patient treatment, helping to reduce the cost of healthcare worldwide.

Avacta joined AIM in August 2006 and is based in Wetherby, England.

For further information visit www.avacta.com